Under construction – not a live service
Sign in
Not yet taking people in TürkiyeNo phase

Sudden optic nerve vision loss in obese adults using GLP-1 receptor agonist drugs

Reviews past records of obese adults on GLP-1 drugs for a sudden vision-loss condition.

Key facts

Who runs it
Istanbul Saglik Bilimleri University
Where
Istanbul, TürkiyeSee the site
Trial code
Registry title
NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study
Status
Not yet recruiting
People taking part
28 people, planned
Started
21 Sept 2026
Expected to end
30 Nov 2026
Type of study
Observational
Treatments tested
  • GLP-1 Receptor Agonist Therapy
Record updated
29 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity (BMI above 30) who used a GLP-1 receptor agonist and had at least two eye exams on record. It reviews past records for NAION and related eye findings.

Age
18 years or older
Sex
All sexes can join
Disease stage
Obesity with a body mass index (BMI) above 30, without diabetes
Earlier treatment
Used a GLP-1 receptor agonist. Not receiving treatment for major depressive disorder and not using antidepressant medication.

Main reasons for not taking part

  • Diagnosis of diabetes
  • Diagnosis of hypertension
  • Previous optic neuritis or similar eye disease
  • Optic disc drusen, optic disc anomaly, glaucoma or other disease involving the optic nerve
  • High hyperopia or small, crowded optic disc

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age 18 years or older
  • Diagnosis of obesity (body mass index > 30)
  • No hearing, speech or cognitive impairment
  • Not receiving treatment for major depressive disorder and not using antidepressant medication
  • At least two eye examinations with measurements on record
  • Verbal agreement to participate

Who cannot take part

  • Previous optic neuritis or similar eye disease
  • Diagnosis of hypertension
  • Optic disc drusen, optic disc anomaly, glaucoma or other disease involving the optic nerve
  • High hyperopia or small, crowded optic disc
  • Not meeting the inclusion criteria or not willing to participate

Where in Türkiye

  • Kanuni Sultan Süleyman Training and Research HospitalIstanbul, TürkiyeContact: GÜLDEN ANATACANo longer taking part

About the trial

What the trial wants to find out

Non-arteritic anterior ischemic optic neuropathy (NAION) is one of the most common causes of sudden, painless, usually unilateral vision loss in adults over 50 years of age, and no proven effective treatment exists. Glucagon-like peptide-1 receptor agonists (GLP-1 RA), such as semaglutide and tirzepatide, are widely used for type 2 diabetes and obesity. Since 2023, case series, cohort studies and regulatory reviews have raised the possibility of an association between semaglutide and NAION, but published evidence is conflicting, and data in non-diabetic obese patients are limited.

Read full original descriptionShow less

This retrospective, single-center, descriptive real-world study will review the existing records of non-diabetic obese adults (BMI > 30) who used a GLP-1 RA and attended the ophthalmology outpatient clinic between January 2025 and February 2026 with at least two eye examinations. The aim is to describe the occurrence and time-related change of NAION and related ophthalmic findings in this population.

The group in the trial

  • GLP-1 RA users (non-diabetic, obese)

    Adults aged 18 or older with BMI \> 30 and no diabetes diagnosis, who used a GLP-1 receptor agonist and had at least two ophthalmic examinations with measurements at the clinic between January 2025 and February 2026.

    Treatment: GLP-1 Receptor Agonist Therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in Non-Diabetic Obese Patients Using Glucagon-Like Peptide-1 Receptor Agonists: A Retrospective Real-World Study
Plain-language title
Sudden optic nerve vision loss in obese adults using GLP-1 receptor agonist drugsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
29 September 2026